Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema
- Sponsor
- Szeged University
- Study ID
- NCT00994799
- Status
- Unknown
Conditions
- Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ranibizumab — DRUG10mg/ml intravitreal injection
- macular grid-pattern laser — RADIATIONmacular grid-pattern laser therapy
Study Details
This study investigates the hypothesis that ranibizumab injection given into the eye is an efficacious and safe treatment option applied for swelling of the macula (site of sharp vision) in diabetes.
Key Dates
- First listed
- Oct 14, 2009
- Start date
- Jul 31, 2009
- Status verified
- Oct 2009
- Completion
- Feb 28, 2011
Study Design
- Enrollment
- 50 participants (estimated)
Arms
- Arm: ranibizumab grouppatients receiving intravitreal ranibizumab for diabetic macular edema
- Arm: laserpatients receiving macular grid-pattern laser therapy
Primary Outcome Measure
Mean change in best corrected visual acuity [ Time Frame: 12 months ]
Central Contacts
- Rozsa Degi, assoc prof+36 30 279 4330
- Barbara B Toth, assistlect+36 30 239 3020
Related Studies
- A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaPHASE2 · Recruiting · Boehringer Ingelheim · Arcadia, California